SENSEI®, Lightpoint's miniaturized probe designed for intra-operative detection of sentinel lymph nodes as well as cancer metastasis through the lymphatic system, has received regulatory approval in the EU.
SENSEI®, our miniaturized probe for minimally-invasive and robot-assisted cancer surgery, has been successfully registered with the FDA and is now authorized for sale in the US.
Dr Lluis Fumado and the team at Hospital del Mar, Barcelona, is the first to initiate in a multi-center clinical trial with SENSEI® in prostate cancer surgery.
TECNASA, Technologias Asociadas will be responsible for the distribution and sale of SENSEI® in Spain and Portugal.
Surgeon's Choice will be responsible for the distribution and sale of SENSEI® across Australia.
Lightpoint has secured $8 Million in new finance from the British Business Bank and follow-on investor.
Dr Jochen Walz and his team at the Institut Paoli-Calmettes in Marseille are the first team in France to use SENSEI® with the da Vinci surgical robot.
First clinical use of SENSEI® in robot-assisted cervical cancer surgery at UMC, Utrecht in the Netherlands using the da Vinci surgical robot.
Lightpoint has appointed Graeme Smith as CEO to focus on the commercialization of the company's recently approved miniaturized surgical probe, SENSEI®.
Lightpoint and Telix will work together to explore how Lightpoint's SENSEI® surgical probe and Telix's molecular imaging agents may be used together for real-time, intra-operative cancer detection.
The brilliant team at UZ Leuven completed their first patient to help us evaluate SENSEI®, our miniature gamma probe for minimally-invasive and robot assisted surgery, in the treatment of prostate cancer.
Lightpoint signs commercial agreement with HOAM Medical (www.hoammedi.com) for distribution of SENSEI®, our miniature gamma probe for minimally-invasive and robot-assisted surgery, in South Korea.